After a literature review and comprehensive screening of the core targets, we identified six key targets (PIK3CA, IGF1R, RPS6KB1, INSR, PRKACA, and PPARG) that are significantly associated with THC’s effect in ameliorating NASH. Here, PRKACA is linked to metabolic dysfunction-associated steatohepatitis.